Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)

NCT ID: NCT00944021

Last Updated: 2019-09-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 69 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-08-31
• Study Completion Date: 2010-05-31

Brief Summary

The trial will evaluate the extended bactericidal activity of 14 consecutive days of oral administration of PA-824 at 50, 100, 150 and 200 mg per day in adult patients with newly diagnosed, uncomplicated, smear positive tuberculosis (TB). A control group will receive standard TB treatment.

Detailed Description

The planned sample size of 15 participants per treatment group is in keeping with other Phase II trials of this type and accounts for the possibility of up to 3 drop-outs per arm, which based on previous studies of this type conducted at these sites, represents a conservative estimate of the expected drop-out rate.

Conditions

Pulmonary Tuberculosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

PA-824 50 mg/qd

Group Type: EXPERIMENTAL

PA-824

Intervention Type: DRUG

50mg

PA-824 100mg/qd

Group Type: EXPERIMENTAL

PA-824

Intervention Type: DRUG

100mg

PA-824 150mg/qd

Group Type: EXPERIMENTAL

PA-824

Intervention Type: DRUG

150 mg

PA-824 200mg/qd

Group Type: EXPERIMENTAL

PA-824

Intervention Type: DRUG

200 mg

Rifafour e-275mg

Group Type: ACTIVE_COMPARATOR

Rifafour e-275 mg

Intervention Type: DRUG

275 mg

Interventions

PA-824

50mg

Intervention Type: DRUG

PA-824

100mg

Intervention Type: DRUG

PA-824

150 mg

Intervention Type: DRUG

Rifafour e-275 mg

275 mg

Intervention Type: DRUG

PA-824

200 mg

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Informed Consent
• Body weight between 40 and 90 kg, inclusive.
• Newly diagnosed, previously untreated, uncomplicated, sputum smear-positive, pulmonary TB.
• A chest X-ray compatible with TB.
• Sputum positive
• Adequate volume of sputum
• Female participants of childbearing potential negative serum pregnancy and agree to use birth control
• Male participants must agree to use contraception throughout participation in the trial and for 12 weeks after last dose.

Exclusion Criteria

• Poor general condition
• Rifampicin-resistant and/or Isoniazid-resistant
• MTB Treatment received within the 3 months prior
• Allergy to the IMP or related substances
• Evidence of extrathoracic TB
• A history of previous TB
• Evidence of serious lung conditions other than TB or uncontrolled obstructive bronchial disease
• History of lens opacity or evidence of lens opacity on slit lamp ophthalmologic examination
• Any evidence of renal impairment
• For males, any evidence or history of abnormality in the reproductive system
• History and/or presence (or evidence) of neuropathy or epilepsy.
• Clinically relevant changes in the ECG
• A history of or current clinically relevant cardiovascular disorder
• Concomitant use of any drug known to prolong QTc interval
• Diabetics using insulin
• Evidence of clinically significant metabolic, gastrointestinal, neurological, psychiatric or endocrine diseases, malignancy, or other abnormalities (other than the indication being studied).
• Any diseases or conditions in which the use of the standard TB drugs or any of their components is contra-indicated, including but not limited to allergy to any TB drug, their component or to the IMP.
• Any disease or conditions in which any of the medicinal products listed in the section pertaining to prohibited medication is used.
• alcohol or drug abuse
• Administration of an IMP prior to Visit 1, within 5 half-lives for that IMP if known. If the half-life of the IMP is unknown within 1 month.
• Pregnant, breast-feeding, or planning to conceive or father a child within twelve weeks of cessation of treatment for males and within one week of cessation of treatment for females.
• Use of any drugs or substances within 30 days prior to dosing known to be strong inhibitors or inducers of cytochrome P450 enzymes
• Any therapeutic agents known to alter any major organ function (e.g., barbiturates, opiates, phenothiazines, cimetidine) within 30 days prior to dosing.
• glucocorticoids within one year prior to dosing.
• HIV infection with helper/inducer T lymphocyte (CD4 cell) count of less than or equal to 300x10-6/L.
• Receiving antiretroviral therapy (ART).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 64 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Global Alliance for TB Drug Development

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Andreas Diacon, MD

Role: PRINCIPAL_INVESTIGATOR

Karl Bremer Hospital

Rodney Dawson, MD

Role: PRINCIPAL_INVESTIGATOR

University of Cape Town Lung Institute

References

Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, van Niekerk C, Erondu N, Ginsberg AM, Becker P, Spigelman MK. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother. 2012 Jun;56(6):3027-31. doi: 10.1128/AAC.06125-11. Epub 2012 Mar 19.

Reference Type: RESULT

PMID: 22430968 (View on PubMed)

Other Identifiers

PA-824-CL-010

Identifier Type: -

Identifier Source: org_study_id